Autoimmunity and graves disease

R. S. Bahn

Research output: Contribution to journalReview article

30 Scopus citations

Abstract

Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

Original languageEnglish (US)
Pages (from-to)577-579
Number of pages3
JournalClinical pharmacology and therapeutics
Volume91
Issue number4
DOIs
StatePublished - Apr 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Autoimmunity and graves disease'. Together they form a unique fingerprint.

  • Cite this